Long-Smith, Caitriona M <br/><br/>
The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.  [electronic resource] 

 -  Neuromolecular medicine  Mar 2013 
 - 102-14 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1559-1174 
<br/><br/><label>Standard No.: </label>10.1007/s12017-012-8199-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alzheimer Disease--genetics<br/>Amyloid beta-Peptides--metabolism<br/>Amyloid beta-Protein Precursor--genetics<br/>Animals<br/>Astrocytes--drug effects<br/>Disease Models, Animal<br/>Female<br/>Frontal Lobe--pathology<br/>Glucagon-Like Peptide 1--analogs & derivatives<br/>Hypoglycemic Agents--pharmacology<br/>Insulin Receptor Substrate Proteins--metabolism<br/>Insulin Resistance<br/>Liraglutide<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Transgenic<br/>Microglia--drug effects<br/>Mutation, Missense<br/>Neuroprotective Agents--pharmacology<br/>Phosphorylation--drug effects<br/>Plaque, Amyloid--prevention & control<br/>Presenilin-1--genetics<br/>Protein Processing, Post-Translational--drug effects<br/>Protein Transport--drug effects<br/>Receptor, Insulin--metabolism<br/>Signal Transduction--drug effects